Evercore Upgrades P&G, Sees End of Sales Downside Risk

Procter and Gamble just got its biggest vote of confidence from Wall Street in two years. Evercore ISI upgraded the consumer giant to Outperform from In Line on Monday, raising its price target to $166 from $161 -- a level that represents roughly 14% upside from the stock's prior close.

The firm's reasoning centers on a sales outlook that's quietly getting better, not worse. Evercore now expects P&G's fiscal first-quarter 2027 organic sales growth to land around 3%, up from a prior forecast of just 2%, according to coverage from Guavy and corroborated by Intellectia.ai's breakdown of the note.

That revision matters more than it sounds. Evercore's thesis is that this upcoming quarter likely marks the end of downside risk to P&G's sales -- a meaningful shift in tone for a stock that's spent much of the year treading water. The firm's EPS estimate for the quarter now sits $0.02 above Wall Street consensus, a small gap but one that signals genuine conviction rather than a token rating bump.

Part of the upgrade thesis rests on what's actually driving growth inside P&G's portfolio. Evercore's analyst noted that higher-margin products -- Olay, Downy, and Pantene among them -- are now contributing more to top-line growth than Pampers, historically one of the company's largest and most reliable categories.

Evercore ISI expects P&G to exit fiscal 2027 with around 4% organic sales growth, a rate the firm says delivers real operating leverage.

That operating leverage point is the crux of the bull case. If sales growth accelerates from 3% to 4% while costs stay disciplined, margins expand even without heroic assumptions about the broader consumer environment.

P&G isn't getting upgraded in a vacuum, either. Moody's recently shifted its outlook on the company to positive, citing strong cash flow and earnings growth tied to strategic pricing, product innovation, and cost-saving initiatives. RBC Capital has separately reiterated its own Outperform rating, pointing to sequential improvement in P&G's U.S. market share -- a detail that supports Evercore's framing of a company past its worst stretch.

Not every signal is unambiguously positive. Goldman Sachs flagged that broader U.S. consumer staples sales, a category that includes much of P&G's business, showed only minimal growth in the latest four-week read from NielsenIQ data. That's a reminder that even as P&G-specific execution improves, the category backdrop isn't exactly roaring.

There's also a smaller headline worth knowing about if you follow the name closely: P&G agreed to modify advertising claims on its Braun Skin i-Expert IPL hair removal device after an Italian antitrust investigation found the "two years hair-free" claim unsubstantiated. It's a minor regulatory footnote, not a fundamental issue, but it adds to the sense that P&G is cleaning up loose ends across the business right now.

For investors sizing up PG here, the actionable level is Evercore's $166 target against a stock that closed well below it Monday. That 14% gap is the upside case if the firm's organic growth thesis plays out as described.

The risk to watch is simple: oil and logistics cost pressures that Evercore itself flagged as not yet factored into P&G's own guidance. If those costs tick up faster than expected, the margin expansion story gets harder to deliver even with sales growth cooperating. Watch the next earnings call for any commentary on input costs -- that's the variable most likely to complicate this upgrade.

P&G isn't a stock that moves in a straight line, but this upgrade -- the firm's first top-line upside call on the name in two years -- gives a concrete reason to watch the upcoming fiscal Q1 print closely. A beat on that 3% organic growth number would validate the thesis fast; a miss would put Evercore's newfound optimism right back on the defensive.